Proderna Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-11-2024
- Paid Up Capital ₹ 13.56 K
as on 15-11-2024
- Company Age 18 Year, 16 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
as on 15-11-2024
- Revenue 32.62%
(FY 2023)
- Profit 27.92%
(FY 2023)
- Ebitda 35.67%
(FY 2023)
- Net Worth 14.39%
(FY 2023)
- Total Assets 16.94%
(FY 2023)
About Proderna Biotech
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 13.56 K .
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Deepak Soota, Arun Mittal, and Prem Goel serve as directors at the Company.
- CIN/LLPIN
U74999DL2006PTC156177
- Company No.
156177
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Dec 2006
- Date of AGM
02 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Proderna Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Soota  | Director | 04-Dec-2006 | Current |
| Arun Mittal | Director | 04-Dec-2006 | Current |
| Prem Goel | Director | 04-Dec-2006 | Current |
Financial Performance and Corporate Structure Insights of Proderna Biotech.
Proderna Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.62% increase. The company also saw a substantial improvement in profitability, with a 27.92% increase in profit. The company's net worth Soared by an impressive increase of 14.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Proderna Biotech?
In 2023, Proderna Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 13 Oct 2008 | ₹2.50 M | Satisfied |
Canara Bank Creation Date: 13 Oct 2008 | ₹2.50 M | Satisfied |
How Many Employees Work at Proderna Biotech?
Unlock and access historical data on people associated with Proderna Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Proderna Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Proderna Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
